Navigation Links
Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
Date:9/24/2009

LAKE FOREST, Ill., Sept. 24 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc.

(Logo:http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Bioniche Pharma has the rights to market and distribute Fomepizole in the United States.

Bioniche will supply Fomepizole Injection in 1.5g /1.5 mL vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has six FDA approved products, of which four were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Antizol(R) is a registered trademark of Paladin Labs.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 Year-End Results
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
3. Bioniche Repays Revolving Credit Facility
4. Bioniche Provides a Corporate Update
5. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
6. Bioniche Represented at House of Commons Sub-Committee on Food Safety
7. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
8. Bioniche Reports Fiscal 2009 Third Quarter
9. Bioniche Provides a Corporate Update
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Bioniche Revolving Credit Facility Maturity Date Amended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Utah (PRWEB) , ... January 17, 2017 , ... ... of accredited, online continuing education for EMS and firefighting professionals, has released four ... (VILT) Solution. These new courses are taught live in an online classroom and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/16/2017)... ... 17, 2017 , ... To provide comfort and fuel during ... fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, guests can ... Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage Soup, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... YORK , Jan. 17, 2016  Attorney Advertising -- ... behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the ... to obtain additional information and assist the investigation by visiting ... concerns whether Anthera and certain of its officers and/or directors ... Act of 1934. ...
(Date:1/17/2017)...  In a letter to President-elect Donald J. ... outlines AARP,s priorities for Americans age 50 and older ... affordable health care coverage, and lowering the cost of ... to President-elect Trump that "Our nearly 38 million members ... to protect their Medicare and Social Security benefits, protect ...
Breaking Medicine Technology: